Michael David Barker

USPTO Granted Patents = 15 (Patent Applications = 3)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 8 (Patent Applications = 8)

Average Co-Inventor Count = 7.2

ph-index = 5

Forward Citations = 94(Granted Patents)

Location History:

Stevenage, Hertfordshire, GB (2003)
Stevenage, GB (2002 - 2020)

Company Filing History:

Glaxosmithkline Intellectual Property Development Limited

patents

1 out of 2,198

Smithkline Beecham Corporation

patents

4. 1 out of 92

Glaxosmithkline Intellectual Property (no.2) Limited

patents

5. 1 out of 832,680

Other

patents

Years Active: 2002-2020

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10815218 - Benzoimidazole derivatives as PAD4 inhibitors (2020-10-27),

2. 10407407 - Benzoimidazole derivatives as PAD4 inhibitors (2019-09-10),

3. 10039755 - 2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors (2018-08-07),

4. 9833449 - 2-(azaindol-2-yl) benzimidazoles as PAD4 inhibitors (2017-12-05),

5. 9670221 - Furopyridines as bromodomain inhibitors (2017-06-06),

6. 9518054 - 2-(azaindol-2-yl) benz imidazoles as PAD4 inhibitors (2016-12-13),

7. 9447074 - Compounds (2016-09-20),

8. 9127003 - 2-(azaindol-2-yl)benzimidazoles as PAD4 inhibitors (2015-09-08),

9. 8993560 - Compounds (2015-03-31),

10. 8633319 - 7-(1H-pyrazol-4-yl)-1,6-naphthyridine compounds as Syk inhibitors (2014-01-21),

11. 7985740 - Purine derivatives as agonists of the adenosine A2A receptor (2011-07-26),

12. 7572915 - Quinoline derivatives as phosphodiesterase inhibitors (2009-08-11),

13. 7566786 - Quinoline derivatives as phosphodiesterase inhibitors (2009-07-28),

14. 6528494 - 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives (2003-03-04),

15. 6426337 - 2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives (2002-07-30),

Title: The Innovations of Michael David Barker

Introduction

Michael David Barker is a notable inventor based in Stevenage, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of PAD4 inhibitors. With a total of 15 patents to his name, Barker's work has the potential to impact the treatment of various serious disorders.

Latest Patents

Among his latest patents are the benzoimidazole derivatives as PAD4 inhibitors. These compounds, defined by specific formulas, are designed to inhibit PAD4 and may be useful in treating a range of disorders. These include rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, and psoriasis. The innovative nature of these compounds highlights Barker's commitment to advancing medical science.

Career Highlights

Throughout his career, Michael David Barker has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Limited. His experience in these organizations has undoubtedly contributed to his expertise and success as an inventor.

Collaborations

Barker has collaborated with several professionals in his field, including John Liddle and David Matthew Wilson. These partnerships have likely enriched his work and fostered innovation in his projects.

Conclusion

Michael David Barker's contributions to the field of pharmaceuticals through his patents and collaborations demonstrate his significant role as an inventor. His work continues to pave the way for advancements in the treatment of various disorders.

This text is generated by artificial intelligence and may not be accurate.